262 related articles for article (PubMed ID: 24739388)
1. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
Kim YG; Seo JH; Kwak JH; Shin KJ
Bioorg Med Chem Lett; 2015 Oct; 25(20):4481-6. PubMed ID: 26343826
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
[TBL] [Abstract][Full Text] [Related]
4. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI.
Kitagawa H; Kumura K; Takahata S; Iida M; Atsumi K
Bioorg Med Chem; 2007 Jan; 15(2):1106-16. PubMed ID: 17095231
[TBL] [Abstract][Full Text] [Related]
5. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel and potent class of FabI-directed antibacterial agents.
Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase.
Tipparaju SK; Joyasawal S; Forrester S; Mulhearn DC; Pegan S; Johnson ME; Mesecar AD; Kozikowski AP
Bioorg Med Chem Lett; 2008 Jun; 18(12):3565-9. PubMed ID: 18499454
[TBL] [Abstract][Full Text] [Related]
8. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).
Mehboob S; Song J; Hevener KE; Su PC; Boci T; Brubaker L; Truong L; Mistry T; Deng J; Cook JL; Santarsiero BD; Ghosh AK; Johnson ME
Bioorg Med Chem Lett; 2015 Mar; 25(6):1292-6. PubMed ID: 25677657
[TBL] [Abstract][Full Text] [Related]
9. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
Miller WH; Seefeld MA; Newlander KA; Uzinskas IN; Burgess WJ; Heerding DA; Yuan CC; Head MS; Payne DJ; Rittenhouse SF; Moore TD; Pearson SC; Berry V; DeWolf WE; Keller PM; Polizzi BJ; Qiu X; Janson CA; Huffman WF
J Med Chem; 2002 Jul; 45(15):3246-56. PubMed ID: 12109908
[TBL] [Abstract][Full Text] [Related]
10. Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.
Kim N; Sohn MJ; Koshino H; Kim EH; Kim WG
Bioorg Med Chem Lett; 2014 Jan; 24(1):83-6. PubMed ID: 24332629
[TBL] [Abstract][Full Text] [Related]
11. Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
Bogdanovich T; Clark C; Kosowska-Shick K; Dewasse B; McGhee P; Appelbaum PC
Antimicrob Agents Chemother; 2007 Nov; 51(11):4191-5. PubMed ID: 17875997
[TBL] [Abstract][Full Text] [Related]
12. FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
Rana P; Ghouse SM; Akunuri R; Madhavi YV; Chopra S; Nanduri S
Eur J Med Chem; 2020 Dec; 208():112757. PubMed ID: 32883635
[TBL] [Abstract][Full Text] [Related]
13. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
[TBL] [Abstract][Full Text] [Related]
14. Aquastatin A, a new inhibitor of enoyl-acyl carrier protein reductase from Sporothrix sp. FN611.
Kwon YJ; Fang Y; Xu GH; Kim WG
Biol Pharm Bull; 2009 Dec; 32(12):2061-4. PubMed ID: 19952429
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening of antibacterial compounds by similarity search of Enoyl-ACP reductase (FabI) inhibitors.
Asse Junior LR; Kronenberger T; Magalhães Serafim MS; Sousa YV; Franco ID; Valli M; Silva Bolzani VD; Monteiro GC; Bruno Prates JL; Kroon EG; Fernandes Mota BE; Santos Ferreira DD; de Oliveira RB; Maltarollo VG
Future Med Chem; 2020 Jan; 12(1):51-68. PubMed ID: 31729258
[No Abstract] [Full Text] [Related]
16. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
Park HS; Yoon YM; Jung SJ; Kim CM; Kim JM; Kwak JH
J Antimicrob Chemother; 2007 Sep; 60(3):568-74. PubMed ID: 17606482
[TBL] [Abstract][Full Text] [Related]
17. A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.
Kwon J; Mistry T; Ren J; Johnson ME; Mehboob S
Bioorg Med Chem; 2018 Jan; 26(1):65-76. PubMed ID: 29162308
[TBL] [Abstract][Full Text] [Related]
18. Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.
Kronenberger T; Asse LR; Wrenger C; Trossini GH; Honorio KM; Maltarollo VG
Future Med Chem; 2017 Feb; 9(2):135-151. PubMed ID: 28128024
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.
Yum JH; Kim CK; Yong D; Lee K; Chong Y; Kim CM; Kim JM; Ro S; Cho JM
Antimicrob Agents Chemother; 2007 Jul; 51(7):2591-3. PubMed ID: 17420210
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]